Form 4: Inozyme Pharma CEO & Chairman Douglas Treco Acquires Shares Through Employee Stock Purchase Plan

Inozyme Pharma, Inc.'s CEO and Chairman, Douglas A. Treco, acquired 2,815 shares of common stock at $0.74 per share through the company's Employee Stock Purchase Plan.

Summary

• Douglas A. Treco, CEO and Chairman of Inozyme Pharma, Inc., acquired 2,815 shares of the company's common stock.
• The transaction occurred on June 25, 2025, at a price of $0.74 per share.
• The shares were purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan (ESPP).
• The purchase price of $0.74 per share represents 85% of the closing price of the Issuer's common stock on April 1, 2025, which was the first trading day of the ESPP purchase period (April 1, 2025, through June 25, 2025).
• Following this transaction, Douglas A. Treco beneficially owns a total of 43,861 shares of Inozyme Pharma, Inc. common stock.

Sentiment

Score: 7

Explanation: The acquisition of shares by a key executive, even through an Employee Stock Purchase Plan, generally indicates confidence in the company's future prospects and aligns management's interests with shareholders.

Positives

• A key executive, Douglas A. Treco, acquired additional shares in the company, which can signal confidence in future performance.
• The acquisition was made through a structured Employee Stock Purchase Plan, indicating a pre-planned investment by management.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing, as it primarily reports a past transaction.

Industry Context

Insider transactions, particularly through Employee Stock Purchase Plans, are common across industries. They reflect an executive's participation in company-sponsored benefit programs and can be viewed as a routine part of compensation and long-term incentive structures.

Comparison to Industry Standards

• Employee Stock Purchase Plans (ESPPs) are a standard benefit offered by many publicly traded companies across various industries, allowing employees to purchase company stock, often at a discount.
• The discount rate of 15% (implied by purchasing at 85% of the closing price) is a common and competitive discount offered in many ESPPs across the market.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive signal, suggesting management's belief in the company's value and future growth.

Key Dates

Recommendation

Keywords

Inozyme Pharma, INZY, Douglas A. Treco, SEC Form 4, Insider Transaction, Stock Purchase, Employee Stock Purchase Plan, ESPP, CEO, Chairman, Beneficial Ownership